Friday, June 30, 2023

Indices closed UP .84% to 1.45%...NICE !!!

 Indices closed the week, month, Q 2 & 6 months on a bullish note.

Expect many pre-announcements of better than expected Q2 just ended....

Here is my portfolio :

Bought BTCC-U.TO...bitcoin ETF in Canada hedged to US$ @ $5.48...there are many version of bitcoin ETF in Canada trading for almost a year in Toronto (TO)

Here is my portfolio weighting :

SHOP        47.35%

AI              40.70%

TSLL          6.46%

PLTR         4.00%

BTCC        1.49%

Next post on Tuesday due to holiday schedule....

Toronto closed on Monday for our Canada Independence Day which IS July 1.....

US markets closed @ 1 PM on Monday

US markets closed on Tuesday for 4th of July, BUT Toronto open full time on Tuesday

World markets are open from Monday with exception from Canada & USA.....

Enjoy your long weekend !!!

BLOG does NOT give buy or sell.

Saleem

12 comments:

Stocks100 said...


Hi Stocktrader,

Sold TSLL @ $18.96

Saleem

Stock Rookie said...

Congrats on booking profits sir!

Stocks100 said...


Hi Stock Rookie,

Thanks for your feedback re TSLL.

Hi Stocktrader,

Added 225% PLTR @ $15.40

Saleem

stocktrader_1996 said...

Hi Saleem,

Nice job with the TSLA spike!

I'm still working on the last weekly numbers - taking it easier today.

Stocktrader

stocktrader_1996 said...

Hi Saleem,

Added to TYGO BMEA HIMS JETD

I have one position cash available - looking for an IONQ pullback

Stocktrader

Stocks100 said...


Hi Stocktrader,

Good luck with more additional shares of long TYGO BMEA HIMS & short on inverse JETD...

I like your IONQ...I will buy right here right now.....go for It....

Saleem

Stock Rookie said...

Hi Salem & Stocktrader,
I followed you both and bought BMEA & PLTR. Thank you for recommendation! GL to us!

Simon

stocktrader_1996 said...

Hi Saleem,

Last week: +3.76% (YTD: +100.66%)
Portfolio Leaders: IONQ(sold) HIMS TYGO(bought) SYM RCL
Portfolio Laggards: BMEA(bought) SQQQ

It was a week of big winners and losers but ultimately the portfolio powered forward and achieved the "magical" triple digit gain on the year. This is both incredible and frightening considering we are only halfway through the year. My gut and chart analysis tells me we need some pullback/digestion, but I can't actually think of a good reason for that to happen, so I'm nervous about my large short/hedge positioning and that it may hamper gains going forward, but it did help me hold onto a good idea like IONQ for a 49% gain in a single week. For now, I will try and stay balanced and keep a little cash available for opportunities.

Holdings: SQQQ(3x normal) JETD PINS TYGO BMEA SCCO HIMS ZENV(1/5th normal), cash 9%

Stocktrader

stocktrader_1996 said...

Hi Saleem,

With IONQ's cash burn and rapid expansion, I am waiting patiently for a secondary offering - I hope I don't miss too much...

Hi Stock Rookie,

Good luck with the blog picks - we are with you!! :)

Stocktrader

stocktrader_1996 said...

Hi Stock Rookie,

Here's the biggest bull/bear on BMEA after the data release last weekend (7/25):

Citi ups Biomea Fusion target to $90, elevates to 'Top Pick'
Citi raised the firm's price target on Biomea Fusion to $90 from $53 and keeps a Buy rating on the shares. The analyst also elevated the shares to Citi's "Top Pick in SMID Biotech." BMF-219 "has passed a critical test of drug worthiness" with the updated data, the analyst tells investors in a research note. The firm says even the most skeptical investors will find it challenging to discredit the latest poster given Biomea's "total transparency in presenting compelling patient-level data across key metrics." The firm's updated model reflects a 65% probability of success and increased 3% peak market share in type 2 diabetes.

efferies downgrades Biomea Fusion, says data 'seem to raise more questions'
As previously reported, Jefferies downgraded Biomea Fusion to Hold from Buy with a price target of $28, down from $36, largely on an increased discount rate. Following the American Diabetes Association update on early data, the firm argues that additional data "seem to raise more questions" on how BMF-219 works in T2D and how to best develop it in the presence of an increasing number of effective therapies. Given the firm's view that it may take a while to see a clear development path and successful commercial application of BMF-219, it is resetting its target, largely on an increased discount rate of 14%, up from 13% previously, the analyst tells investors.

Stocktrader

Stock Rookie said...

Thank you so very much Stocktrader for the valuable inf sir!🙏

Stocks100 said...


Hi Stocktrader,

Last week UP 10.70%

YTD UP 108.73%

Saleem